- Home
- ILMN vs ENTG Comparison
ILMN vs ENTG Comparison
Compare ILMN & ENTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- ENTG
- Stock Information
- Founded
- ILMN 1998
- ENTG 1966
- Country
- ILMN United States
- ENTG United States
- Employees
- ILMN N/A
- ENTG N/A
- Industry
- ILMN Medical Specialities
- ENTG Plastic Products
- Sector
- ILMN Health Care
- ENTG Industrials
- Exchange
- ILMN Nasdaq
- ENTG Nasdaq
- Market Cap
- ILMN 15.9B
- ENTG N/A
- IPO Year
- ILMN 2000
- ENTG 2000
- Fundamental
- Price
- ILMN $77.01
- ENTG $75.65
- Analyst Decision
- ILMN Buy
- ENTG Strong Buy
- Analyst Count
- ILMN 18
- ENTG 9
- Target Price
- ILMN $141.94
- ENTG $127.67
- AVG Volume (30 Days)
- ILMN 2.2M
- ENTG 2.8M
- Earning Date
- ILMN 05-01-2025
- ENTG 04-30-2025
- Dividend Yield
- ILMN N/A
- ENTG 0.47%
- EPS Growth
- ILMN N/A
- ENTG 60.83
- EPS
- ILMN N/A
- ENTG 1.93
- Revenue
- ILMN $4,372,000,000.00
- ENTG $3,241,208,000.00
- Revenue This Year
- ILMN $0.69
- ENTG $8.48
- Revenue Next Year
- ILMN $4.91
- ENTG $10.10
- P/E Ratio
- ILMN N/A
- ENTG $44.54
- Revenue Growth
- ILMN N/A
- ENTG N/A
- 52 Week Low
- ILMN $77.54
- ENTG $83.97
- 52 Week High
- ILMN $156.66
- ENTG $147.57
- Technical
- Relative Strength Index (RSI)
- ILMN 30.53
- ENTG 25.26
- Support Level
- ILMN $77.54
- ENTG $95.67
- Resistance Level
- ILMN $82.76
- ENTG $87.91
- Average True Range (ATR)
- ILMN 2.89
- ENTG 3.25
- MACD
- ILMN 0.51
- ENTG -1.46
- Stochastic Oscillator
- ILMN 7.53
- ENTG 2.30
Stock Price Comparison Chart: ILMN vs ENTG
■ ILMN
■ ENTG
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Share on Social Networks:
0